Insurance

Medicare Coverage for GLP-1 Medications: What to Know

GLP-1 Companion · 9 min read

Medicare covers GLP-1 medications selectively, and the rules depend heavily on what diagnosis the medication is prescribed for and which specific drug is involved. For many Medicare beneficiaries, particularly those who need GLP-1 therapy for obesity management rather than type 2 diabetes, the coverage landscape has historically been limiting — though important changes are in progress. This guide explains the current state of Medicare GLP-1 coverage as of April 2026.

Medicare Part D Coverage for Diabetes-Indicated GLP-1s

Medicare Part D (prescription drug coverage) covers GLP-1 medications that are FDA-approved for the treatment of type 2 diabetes, including Ozempic (semaglutide), Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Victoza and Saxenda's predecessor liraglutide formulations, and others prescribed with a T2D diagnosis. This coverage applies when the medication is on your specific plan's formulary and your prescriber has documented the type 2 diabetes indication.

• Ozempic (semaglutide 0.5–2 mg, for T2D): covered under most Part D plans; requires prior authorization; typical Part D cost-sharing after deductible is $35–$100/month
• Mounjaro (tirzepatide for T2D): covered under many Part D plans as of 2025–2026; prior authorization typically required; formulary tier placement varies by plan
• Rybelsus (oral semaglutide for T2D): covered under Part D when prescribed for T2D; subject to step therapy at some plans, requiring prior metformin trial
• Victoza (liraglutide for T2D): older agent, often covered with lower cost-sharing due to longer market history

Wegovy and Zepbound for Obesity: The Coverage Gap

This is where Medicare's GLP-1 coverage creates significant frustration. Wegovy (semaglutide 2.4 mg, FDA-approved for chronic weight management) and Zepbound (tirzepatide, FDA-approved for chronic weight management) are not covered by Medicare Part D when prescribed solely for obesity. This prohibition dates to a 2003 law that explicitly excluded "drugs for weight loss" from Medicare Part D coverage.

This means that a Medicare beneficiary with a BMI of 40 and no diabetes diagnosis — someone with clear clinical need for pharmacologic obesity treatment — receives no Part D coverage for Wegovy or Zepbound. Without insurance, these patients face the full list price of over $1,000 per month, and unlike commercially insured patients, they cannot use manufacturer savings cards (which explicitly exclude Medicare beneficiaries).

The Important Exception: Cardiovascular Disease and the SELECT Trial

In 2024, Novo Nordisk received an expanded FDA approval for Wegovy based on the SELECT trial results, which demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — by 20% in adults with established cardiovascular disease and obesity but without diabetes. This cardiovascular risk reduction indication was a landmark approval because it reframed Wegovy not as a "weight-loss drug" but as a cardiovascular medication.

Critically for Medicare patients, CMS (Centers for Medicare and Medicaid Services) subsequently determined that Wegovy covered under the cardiovascular disease indication falls within Medicare Part D coverage, because it is being used to prevent cardiovascular events — not solely for weight loss. This means that Medicare beneficiaries who meet all of the following criteria may be eligible for Part D coverage of Wegovy.

• Established cardiovascular disease (defined as prior MI, prior stroke, or symptomatic peripheral arterial disease)
• BMI of 27 kg/m² or greater
• No type 2 diabetes diagnosis (if T2D is present, Ozempic or Mounjaro would typically be prescribed instead)
• Prescription written specifically under the cardiovascular risk reduction indication

This exception is significant but limited in scope. Medicare beneficiaries with obesity who do not have documented cardiovascular disease remain without coverage for weight-management-indicated GLP-1s.

Why Manufacturer Assistance Programs Are Not Available to Medicare Beneficiaries

A key source of confusion for Medicare patients is that the manufacturer savings programs — Novo Nordisk's savings cards, Lilly's savings cards — that bring costs to $25 or $0 per month for commercially insured patients are explicitly unavailable to Medicare beneficiaries. This is not a choice by manufacturers but a federal anti-kickback statute requirement. Using manufacturer copay assistance on a Medicare claim is considered an illegal inducement under federal law, exposing both the manufacturer and the pharmacy to liability.

However, manufacturer patient assistance programs (PAPs), which are needs-based and provide medication at no cost to qualifying uninsured or very-low-income patients, are a separate category. Some PAPs do have limited pathways for Medicare beneficiaries who cannot afford their cost-sharing. Contact NovoCare or Lilly Cares directly to ask about Medicare-specific assistance eligibility.

Inflation Reduction Act Impact on GLP-1 Costs

The Inflation Reduction Act (IRA) of 2022 made several changes to Medicare drug pricing that affect GLP-1 access.

• $2,000 annual out-of-pocket cap on Part D drug spending (effective 2025): once you hit $2,000 in out-of-pocket drug costs, your cost-sharing for covered drugs drops to $0 for the rest of the year
• Medicare Drug Price Negotiation: the IRA gave CMS authority to negotiate prices for certain high-cost drugs directly with manufacturers; GLP-1 medications may be candidates for negotiation in future cycles
• Smoothing provisions: Part D plans can spread out-of-pocket costs evenly across the year rather than requiring large upfront payments, improving cash flow for patients on expensive medications

Pending Legislation: The Treat and Reduce Obesity Act

The Treat and Reduce Obesity Act (TROA) has been introduced in multiple congressional sessions. If passed, it would amend Medicare law to explicitly allow Part D coverage of FDA-approved anti-obesity medications, including Wegovy and Zepbound, for Medicare beneficiaries with obesity regardless of a cardiovascular disease diagnosis. As of April 2026, TROA has not been enacted, but it continues to gain bipartisan support. The SELECT trial data providing cardiovascular evidence for semaglutide has strengthened the argument for legislative change.

Practical Workarounds for Medicare Patients

While legislation is pending, Medicare beneficiaries who need GLP-1 therapy for obesity management have limited but real options.

• If you have documented cardiovascular disease: ask your prescriber to write Wegovy specifically under the cardiovascular risk reduction indication and work with your Part D plan on coverage
• If you have type 2 diabetes: Ozempic or Mounjaro are Part D-covered for T2D and provide significant weight loss benefit alongside glycemic control
• If you have pre-diabetes or insulin resistance: discuss with your prescriber whether a T2D indication may apply, or whether lifestyle intensification with metformin is a covered bridge therapy
• Medicare Advantage plans: some Medicare Advantage (Part C) plans have more generous formularies than traditional Part D and may cover weight-management GLP-1s; check your specific plan's drug formulary
• Low Income Subsidy (Extra Help): if you qualify for the LIS/Extra Help program, your Part D cost-sharing is significantly reduced for covered drugs

The gap in Medicare coverage for anti-obesity medications reflects outdated policy rather than clinical evidence. Multiple major medical societies, including the American Heart Association, the American Diabetes Association, and the Obesity Medicine Association, have formally called for Medicare to cover GLP-1 medications for obesity. Change is likely; the timeline remains uncertain.

What to Do Now

If you are a Medicare beneficiary who needs GLP-1 therapy, have an honest conversation with your prescriber about your complete cardiovascular and metabolic health profile. In many cases, the best path forward is identifying a covered indication — T2D, prediabetes with cardiovascular risk factors, or established CVD — that supports prescribing under a Medicare-covered framework. If no such indication exists, ask about the Part D out-of-pocket cap, PAP eligibility, and whether your Medicare Advantage plan offers better coverage than traditional Part D.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.